Houlihan Financial Resource Group’s Bristol-Myers Squibb BMY Stock Holding History

Houlihan Financial Resource Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$54K	Buy	+847	New	+$51K	0.03%	166

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Houlihan Financial Resource Group's BMY Position: Q3 2020 in Review

Houlihan Financial Resource Group opened a new position in Bristol-Myers Squibb (BMY) in Q3 2020: 847 shares worth $54K. The stake represents 0.03% of the portfolio and ranks #166 among its holdings.

2,214 funds tracked by Wall St. Rank hold BMY as of Q3 2020.

Houlihan Financial Resource Group held 847 shares of Bristol-Myers Squibb worth $54K as of Q3 2020.
Bristol-Myers Squibb was a new Houlihan Financial Resource Group position in Q3 2020.
Bristol-Myers Squibb made up 0.03% of Houlihan Financial Resource Group's portfolio in Q3 2020, its #166 holding.
2,214 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2020.

Based on Houlihan Financial Resource Group's 13F filing for Q3 2020, filed 13 Nov 2020.